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Resident memory T cells are a cellular reservoir
for HIV in the cervical mucosa
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HIV viral reservoirs are established very early during infection. Resident memory T cells
(TRM) are present in tissues such as the lower female genital tract, but the contribution of this
subset of cells to the pathogenesis and persistence of HIV remains unclear. Here, we show
that cervical CD4+TRM display a unique repertoire of clusters of differentiation, with
enrichment of several molecules associated with HIV infection susceptibility, longevity and
self-renewing capacities. These protein profiles are enriched in a fraction of CD4+TRM
expressing CD32. Cervical explant models show that CD4+TRM preferentially support HIV
infection and harbor more viral DNA and protein than non-TRM. Importantly, cervical tissue
from ART-suppressed HIV+ women contain high levels of viral DNA and RNA, being the TRM
fraction the principal contributor. These results recognize the lower female genital tract as an
HIV sanctuary and identify CD4+TRM as primary targets of HIV infection and viral persis-
tence. Thus, strategies towards an HIV cure will need to consider TRM phenotypes, which are
widely distributed in tissues.
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The major hurdle to HIV
-1 eradication is the establishment
of reservoirs harboring latent HIV and low levels of viral
replication while on antiretroviral therapy (ART)1. The
characteristics of this reservoir and the viruses that emerge during
ART interruption suggest that it is established in different tissues,
including the mucosa2, a few days after becoming infected. Early
treatment with ART can prevent viremia and limit the size of the
viral reservoir, but it does not prevent its establishment1. While
the main HIV cellular target, activated CD4+ T cells, die mas-
sively during the initial infection, it is assumed that a very low
proportion of the initially infected cells live long enough to be
able to enter into a resting state (quiescence), establishing a
memory reservoir. The fact that memory CD4+ T cells generate
long-term protection (even during the whole life of the indivi-
dual), without needing a second exposure to the pathogen and
considering that its physiology includes the homeostatic pro-
liferation of these cells, supports theories that only the long life of
this population is sufficient for the maintenance of these reser-
voirs2. In addition, the presence of pharmacological and immu-
nological sanctuary sites has been associated to residual viral
replication in tissues, thus contributing to viral persistence3,4.
It has been determined that in blood the virus persists mostly
in the central memory and, to a lesser extent, in the transitional
memory (CD27+) subsets5. Within the memory compartment,
CD4+ T follicular helper cells recently emerged as an important
population that sustains HIV reservoirs6. Likewise, the con-
tribution to the total HIV reservoir of the stem cell-like memory
T cells (TSCM), defined mainly by the expression of CD95 in a
population phenotyped as naive, increases significantly after long-
term therapy, compared to other memory subpopulations7. Fur-
ther, CD4+ T cells with high expression of CD2 have been pos-
tulated as potentially associated with latently infected cells8. More
recently, CD32 expression in a subset of CD4+ T cells was also
associated to HIV-latently infected cells9, but soon after it was
demonstrated to be linked to transcriptionally active infected
cells10–13. Similarly, the effector memory phenotype and the
expression of CD30 have also been associated to transcriptionally
active infected cells14,15. Nevertheless, most of these populations
have been determined in blood, while in tissues is where the main
reservoir resides. In this sense, assessment of viral DNA (vDNA)
and viral RNA (vRNA) positive cells in effectively ART-treated
macaques (plasma vRNA < 50 copies/mL) has shown virus
remaining in every tissue examined3. Further, in ART-suppressed
patients proviral DNA determined in cells obtained from ileum
biopsies16 or from bronchoalveolar lavage17 is enriched compared
to blood, and even CD4+ T cells from adipose tissue represent a
niche of viral persistence18. In macaque models these reservoirs
are established within three days after infection19 and therefore
target cells present in the initially infected tissues may have great
relevance in the generation and persistence of these reservoirs.
Thus, tissues from the female genital mucosa, the portal of entry
of HIV, may represent an unrecognized reservoir, as
suggested20,21. In this sense, the most abundant hematopoietic
cells in the cervix are CD14+/CD68+ cells, compatible with dif-
ferent myeloid phenotypes, and CD4+ T cells22,23 likely belong-
ing to the resident memory T cell (TRM) phenotype, according to
their CD69 expression24.
CD4+ TRM reside in various tissues in mice and humans and
some of their phenotypic characteristics have recently been
established25,26. Since CD69 is a hallmark of these cells and, in
general, the majority of cervical CD4+ T cells express this acti-
vation marker24, this would question the role for these cells in the
establishment of viral latency, as presumably they do not repre-
sent quiescent cells. However, the expression of this molecule in
TRM may have a role in tissue retention, since it regulates the
sphingosine-1 phosphate receptor, which in turn participates in
the exit of lymphocytes to tissues25,26. Further, in TRM from lung
or spleen, CD69 expression is not associated with expression of
activation markers, namely CD25, CD38 and HLA-DR. This
phenotype, together with a reduced expression of the prolifera-
tion marker Ki67 and maintenance of expression of CD127 and
CD28, suggests that TRM may have a low turnover and a more
quiescent state, which could prevent inadequate activation in
tissues with high antigenic exposure while promoting the long-
evity of these cells25.
In the macaque model of SIV infection, gut CD69+CD4+
T cells, which are predominant in this tissue, are the main viral
target that is rapidly depleted by direct infection27. Furthermore,
it has been shown that HIV entry in cytobrush-derived cervical
CD4+ T cells of HIV− women is preferential in activated cells
expressing CD69, α4β7, and α4β1, and its enhanced susceptibility
strongly correlates with increased CCR5 expression28. While
these studies highlight tissue CD69+CD4+ T cells as preferential
targets of acute HIV infection, it remains to be elucidated if these
cells belong to the TRM phenotype and if they encompass a long-
term reservoir during ART. Thus, although CD69 expression on
TRM may have precluded their study in relation to HIV-1 latency,
several of their features suggest that these cells could contribute to
HIV persistence: HIV-1 susceptibility, wide tissue distribution
(including mucosal portals of entry for HIV) and local pro-
liferation and longevity of different antigen specificities25,29. Here,
to resolve if CD4+ TRM embody a cellular HIV-1 reservoir, we
focus on cervical tissue, which we also postulate may represent an
unrecognized HIV sanctuary. After detailed analysis of the CD4+
TRM protein profile in these mucosal tissues, which predicted
increased susceptibility and long-term persistence, we show pre-
ferential infection of these cells using a cervical ex vivo model of
HIV infection. To address if CD4+ TRM are indeed a source of
HIV persistence, we studied cervical tissues from aviremic ART-
treated HIV-1 infected women. Critically, we detect higher vDNA
content in cervical tissues compared to contemporaneous blood
samples from these patients, and show that CD4+ TRM harboring
vDNA and vRNA are the main contributors to this reservoir.
Results
Evaluation of TRM cell markers in cervical CD69+ cells. In
recent extensive TRM analyses of human tissues25,26, the female
genital tract has not been included and, thus, the precise char-
acteristics of cervical TRM remain largely undefined. Still, in the
female reproductive tract of mice, a recent publication demon-
strates that >90% of the CD4+ T cells are essentially TRM30. In
order to confirm that CD69 expression in these human mucosal
tissues defines cells compatible with a TRM profile reported by
others25,31,32, we first analyzed the expression of several tran-
scriptional factors and surface proteins previously associated to
TRM in a small group of samples. The gating strategy used for
these analyses and examples of the expression of these markers in
the CD69− or the CD69+ fraction of CD4+ T cells derived from
cervical tissues are shown in Fig. 1a, b, respectively. As reported
for human and mouse TRM32, Eomes and T-bet were mostly
absent from cervical CD69+ CD4+ T cells, while a median of
1.51% and of 3.5% CD69−CD4+ T cells expressed Eomes and
T-bet, respectively (Fig. 1c, p= 0.0625 for T-bet). As recently
reported for CD69+ CD8+ T cells derived from other human
tissues25, Hobit was minimally expressed in the CD69− fraction
(median of 1.71%), but absent from the CD69+ CD4+ T cells
(p= 0.0625). S1PR1 and CCR7, molecules expected to be down-
regulated in TRM25,31,32, were only detected in 3.18% and 3.05% of
the CD69+ CD4+ T cells, respectively (Fig. 1c, p= 0.0156 for
CCR7). In addition, CD49a and PD-1, the expression of which
has also been associated to the core signature of TRM25, were
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remarkably higher in CD69+ CD4+ T cells with values of around
40.4% for CD49a and of 76.45% for PD-1 compared to the
CD69− fraction (median values of 4.26% for CD49a and of 36.3%
for PD-1, p= 0.0156 for PD-1 and p= 0.0313 for CD49a). All
together, these analyses confirmed that >95% of the CD4+ T cells
expressing CD69 in cervix are phenotypically associated to bona
fide TRM25,31,32.
CCR5+ CD4+ TRM protein expression signature in cervix. In
order to determine if CD4+ T cells expressing CD69, from now
on called TRM, represent a reservoir for HIV, we first further
characterized the expression profile of TRM as potential HIV-1
targets. Of note, for these analyses, we considered endocervix and
ectocervix separately, since differences exist between these
mucosal tissues in terms of structure, cellular components and
ex vivo HIV replicative capacity23. Considering that HIV-1 iso-
lates from newly infected individuals predominantly use CCR5 as
a co-receptor, we performed a detailed analysis of the phenotype
of cervical CD4+ CCR5+ CD69+ (TRM) and CD69− (non-TRM)
cells from HIV uninfected tissues. Moreover, since we observed
that a fraction of cervical CD4+ TRM consistently expressed low
levels of CD32 in uninfected tissues, a molecule which expression
has been associated with the identification of transcriptionally
active infected cells during HIV infection10,11,13, we analyzed this
fraction separately to determine phenotypic characteristics
that could render these cells more vulnerable to HIV infection.
Figure 2a shows the general gating strategy established for these
analyses (which follows the gating already established in Fig. 1a).
Since several recent papers focused on demonstrating that CD32
expression does not enrich for HIV-latently infected cells raised
concerns on the purity of these cells33–35 and, in order to elim-
inate potential contamination by B cells doublets (CD32 high
subset), we only analyzed the fraction of CD4+ T cells with dim
expression of CD32. We used the levels of CD32 expression in B
cells (indicated with a dotted black line, Fig. 2a) and of the cor-
responding fluorescence minus one control (Supplementary
Fig. 1a) to define a narrow dim CD32+ gate. Further, the exis-
tence of these cells in tissue was confirmed by Amnis imaging
flow cytometry, which allowed visualization of individual CD4+
CD69+ (TRM) cells expressing dim levels of CD32 (Supplemen-
tary Fig. 1b and 1c). These data together with recent publications
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Fig. 1 CD4+ TRM identification in cervix. a General gating strategy for phenotyping of CD4+ T cells obtained from cervicovaginal tissue of healthy donors.
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demonstrating that CD32–RNA correlates with HIV transcrip-
tional activity in T cells from the gut13, and from lymph nodes10,
not only confirms their existence in human tissues, but also raises
interest on defining their nature.
Out of total CD4+ T cells, a median of 45.8% expressed CCR5
in ectocervix and a median of 41.9% expressed CCR5 in
endocervix (Fig. 2b). Further, the median frequency of TRM
within total CD4+ T cells or within CD4+ CCR5+ T cells was
around 80% in both tissues (Fig. 2b). Also, a small subset of CD4+
CCR5+ TRM expressed HLA-DR or CD32, which in the case of
CD32+ were significantly more frequent in ectocervix than in
endocervix (p= 0.031, Fig. 2c). Importantly, while HLA-DR
expression was similar in CD4+ CCR5+ regardless of CD69
expression, with a median of 5.9% and 3.7% in TRM and of 9.9%
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and 5.3% in non-TRM for ectocervix and endocervix respectively;
CD32 expression was strongly associated to TRM compared to
non-TRM (median of 14.3% and 8.1% in TRM vs. 5.2% and 3.7% in
non-TRM for ectocervix and endocervix respectively; p= 0.031 for
ectocervix and p= 0.004 for endocervix, Fig. 2c).
Then, we analyzed the expression of several surface markers
related to HIV-susceptibility and persistence in a total of three
different CD4+ CCR5+ T cell subsets: non-TRM, CD32− TRM and
CD32+ TRM (Fig. 2a). Examples of individual markers are shown
in Supplementary Fig. 2a. We observed that TRM, including CD32+
TRM, expressed significantly higher levels of CD103 (integrin αE)
than non-TRM in ectocervix (p= 0.031 in both cases) and mainly
in endocervix (p= 0.008 in both cases, Fig. 2d). This was expected
since CD103 is associated to intraepithelial retention of CD8+ TRM
and, to less extent, of CD4+ TRM25,26. Other integrins have also
been associated with retention of TRM in tissues, and we observed
that in cervical tissue, integrin α1 (CD49a) is highly associated to
CD4+ CCR5+ T cells displaying a TRM phenotype (p < 0.035 for all
comparisons, Fig. 2e). Additionally, we detected an enrichment of
α4β7 expression on CD32− and CD32+ TRM in the endocervix and
on CD32+ TRM in the ectocervix (p= 0.031 for all comparisons,
Fig. 2f), indicating that some TRM could represent preferential
targets for HIV-128,36. Other HIV co-receptors, such as CXCR4
and CXCR637, were also more frequent in the TRM fractions, where
CD32+ TRM presented even higher frequencies compared to TRM
not expressing CD32 (Fig. 2g, h). Expression of CCR6, a
chemokine receptor associated to T helper 17 (Th17) cells, was
also strongly associated to TRM and, mostly, to CD32+ TRM from
the endocervix, which again showed even higher expression
compared to CD32− TRM (p= 0.008, Fig. 2i).
We also studied the presence of several interleukin receptors
(IL), namely CD122, CD132 and CD127, as they may confer
characteristics of longevity and homeostatic proliferation, with
strong implication for maintenance of HIV reservoirs5. CD122
(β-chain) and CD132 (γ-chain) together form the IL-2 and IL-15
receptors, while CD127 (α-chain) and CD132 form the IL-7
receptor. We detected higher frequency of all three IL receptors in
CD4+ CCR5+ TRM compared to non-TRM in both tissues (p <
0.032 for all comparisons, Fig. 2j–l). However, CD122 and CD132
expression was associated to a small fraction of CD4+ CCR5+
TRM, which was higher in the CD32+ TRM fraction compared to
the CD32− fraction (Fig. 2j, k). In contrast, CD127 was expressed
in a median of 34.8% of non-TRM and in > 55% of CD32+/− TRM,
confirming that, as occurs with other tissues25, there is also
retention of this receptor in memory cells from the cervical
mucosa (Fig. 2l). Surprisingly, while the frequency of each IL-
chain individually was remarkably higher in TRM compared to
non-TRM, there were few cells co-expressing CD132 and CD122,
or CD127 and CD132 within the CD32− TRM fraction
(Supplementary Fig. 2b and 2c). In contrast, a small but
significant fraction of cells co-expressing these receptors was
found in non-TRM compared to TRM, while CD32+ TRM showed
even higher frequencies (Supplementary Fig. 2b and 2c). Further,
we also analyzed CCR7, which was minimally expressed in all
subsets (<5% in general) and, as expected, more associated to
non-TRM that will recirculate (p= 0.031, Supplementary Fig. 2d).
CXCR3 expression was frequent in CD32− TRM and even more
so in CD32+ TRM of both tissues (p < 0.032 in all cases); CD161
was highly expressed in both CD4+ CCR5+ TRM cell fractions
(p < 0.032 for each comparison), as shown before for other TRM
phenotypes in tissue26; while CCR2 and γδ T cells were hardly
detected in any of the subsets studied, except for the CD32+ TRM
fraction resident in the endocervix, which showed higher
expression of CCR2 compared to non-TRM (p= 0.031, Supple-
mentary Fig. 2e-h).
Together, these data not only confirm expression of some of
the markers associated to the TRM phenotype in other tissues25,26
in cervical CCR5+ TRM, but also strongly suggest two concepts
related to our hypothesis: (1) TRM express several molecules that
may render them highly susceptible to HIV infection (namely
α4β7, CXCR4, CXCR6 and CCR6), and (2) these cells are
potentially self-renewed and maintained long-term in tissues (i.e.,
CD122, CD132, CD127). Both concepts apply to TRM in general
and, in particular, to a small fraction of TRM co-expressing low
levels of CD32, which is even more enriched in most of these
surface proteins. Thus, although CD32 expression in blood is
associated to concomitant expression of CD69 indicating early
activation10,11, in cervical tissue CD4+ T cells expressing CD32
are enriched in markers associated to truthfully TRM phenotypes.
Overall, considering that the TRM phenotype is the predominant
CD4+ T cell subset in cervical mucosal tissues and their quiescent
state, exemplified by low HLA-DR here or, as reported before, low
Ki6725, these cells are strong candidates to embody viral
reservoirs in different peripheral tissues.
CD4+ TRM are preferentially infected during ex vivo infection.
In order to demonstrate that CD4+ TRM from cervix represent a
significant cellular reservoir, we first aimed to address if this
subset supports infection ex vivo and which are the dynamics of
CD69 after HIV infection in these tissues. For this, cervicovaginal
tissues from healthy donors were infected with 7200 TCID50 of an
HIV-1BaL viral stock38 for 10–12 days, and infection was mea-
sured by flow cytometry analysis of intracellular p24 staining and
by cell-associated HIV-1 DNA in purified subsets. Since CD4 and
CCR5 molecules are down-regulated by the accessory protein Nef
during HIV-1 infection39, we analyzed p24 viral antigen expres-
sion in a gate including CD4+ and CD4−(CD8−) T cells, as
shown in the gating strategy (Fig. 3a). For each individual cervical
explant infected, the frequency of p24+ cells ranged from 1.92 to
13.4% of CD4+/− T cells (median of 7.3%), in all cases evidencing
CD4 down-regulation (Fig. 3b). When analyzed by subsets,
expression of p24 viral antigen was significantly higher in TRM,
CD103+ TRM and CD32+ TRM compared to non-TRM (p= 0.004,
p= 0.020 and p= 0.008 respectively; Fig. 3b). This increase cor-
responded to a median of 5.02 times more infection in TRM
compared to non-TRM, and of 7.09 times more in the case of
Fig. 2 CCR5+ CD4+ TRM protein expression signature in cervix. a Gating strategy for phenotyping of CD4+ T cells obtained from cervicovaginal tissue of
healthy donors. Based on the gating strategy shown in Fig. 1a, a lymphocyte gate (marked in red) was selected in a plot where dead and CD19+ were
excluded. From one hand, CD3+ CD4+ T cells and then CCR5 positive cells were selected to further analyze three different subsets based on CD69 and
CD32 expression: non-TRM (yellow gate), TRM CD32− (orange gate) and TRM CD32+ (blue gate). Of note, to identify CD4+ T cells expressing low levels of
CD32 (CD32dim, blue gate), we previously defined a gate of exclusion in putative B cells (CD19+, depicted in dotted black lines) as these cells express high
levels of CD32. b Frequency of diverse subsets within CD4+ T cells from human ectocervix (n= 6) and endocervix (n= 9). c Frequency of diverse subsets
within CD4+ CCR5+ T cells from human ectocervix (n= 6) and endocervix (n= 9). d–l Frequency of expression of diverse cell-surface proteins within
three different CD4+CCR5+ T cell subsets; namely CD69− non-TRM (yellow), CD32− TRM (orange) and CD32+ TRM (blue), in human ectocervix (n= 6)
and endocervix (n= 7 for 2e, 2f; n= 8 for 2d, 2h, 2i, 2j, 2k, 2l; n= 9 for 2b, 2c, 2g). Lines and error bars represent median and interquartile ranges. All
statistical comparisons were performed using Wilcoxon matched-pairs signed rank test. Source data are provided as a Source Data file
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Fig. 3 TRM are preferentially infected in the cervical explant model of HIV infection. a General gating strategy for phenotype analyses and intracellular p24
detection in CD4+/− TRM and non-TRM obtained from cervicovaginal tissue infected ex vivo with HIV-1BaL strain. Gating strategy consisted of a lymphocyte
gate based on FSC vs. SSC, followed by doublet exclusion, hematopoietic CD45+ cells, live CD3+ T cells with CD19+ cells exclusion, further B cell exclusion
and a CD4+/− T cell gate from where the different gates shown were quantified: CD4+/− non-TRM (purple) or CD4+/− TRM (orange) or HLA-DR/
CD32dim expression. An example of p24 expression from an infected and a non-infected sample is shown. b Frequency of p24 viral antigen in total
CD4+/− cells (green), CD4+/− non-TRM (purple), CD4+/− TRM (orange), CD4+/− CD103+ TRM and CD4+/− CD32+ TRM detected after 10–12 days of
ex vivo infection and measured by flow cytometry (n= 9, except for CD4+/− CD32+ TRM where n= 8). c Number of HIV-DNA molecules per cell in non-
TRM and TRM detected after 10–12 days of ex vivo infection and measured by qPCR (n= 7). d Frequency of non-TRM and TRM from the total p24 positive
cells measured by flow cytometry (n= 9). e Frequency of HLA-DR expression in different subsets based on their expression of p24 viral antigen after
10–12 days of ex vivo infection (n= 9, except for CD4+/− CD32+ TRM where n= 8). f Number of HIV-DNA molecules per cell in TRM CD32+ and TRM
CD32− detected after 10–12 days of ex vivo infection and measured by qPCR (n= 4). g CD32 frequency in p24+ TRM compared to p24− TRM, measured by
flow cytometry (n= 8). For b and e the median is shown as a solid line, the box indicates the 25–75 percentile range, while the whiskers show the range.
Statistical analysis consisted of a Wilcoxon matched-pairs signed rank test. Source data are provided as a Source Data file
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CD32+ TRM. Moreover, regardless of the frequency of infection,
cell-associated HIV-1 DNA measured by qPCR was more
abundant in CD4+/− TRM with a median of 4.4 vDNA molecules/
cell compared to 0.43 in non-TRM (p= 0.016, Fig. 3c). This
finding was also observed for productively infected cells, namely
CD4+/− p24+ cells, which contained higher proportion of TRM
(>50% in all cases) than of non-TRM (p= 0.004, Fig. 3d).
Unexpectedly, HLA-DR expression in all subsets from these
tissues remained very low, regardless of productive infection
(Fig. 3e). As shown, the percentages of this marker were most
often <20% in all subsets. Productive infection (p24+) of total
TRM was associated with a significant increase of HLA-DR
expression compared to their uninfected counterparts (p= 0.027;
Fig. 3e). Yet, these values were disproportionally lower than the
levels observed on HIV infected cells from blood where, for
example, CD32+ CD4+ infected cells have been shown to have
frequencies of HLA-DR expression >80%10. These data suggest
that in cervical tissue activation markers and their dynamics may
not be comparable to blood. In fact, since HIV infection per se
could induce up-regulation of CD69 on infected cells from
peripheral blood, we determined the dynamics of CD69
expression and HLA-DR over 10 days of infection in cervical
tissue (Supplementary Fig. 3a). Surprisingly, the frequency of
CD69 expression decreased over time, with no significant changes
in HLA-DR expression, similarly to what we observed in the
concomitant non-infected control.
In addition, we separated CD69+ and CD69− CD4+ T cells
from fresh cervical suspensions, which we immediately infected to
evaluate infection (p24) and CD69 expression. From a total of four
individual tissues, a median of 3.23% CD69+ were p24+ 3 days
after infection, while only in one out of four tissues we detected few
p24 positive cells (0.21%) in the CD69− fraction (Supplementary
Fig. 3b). Moreover, in these experiments we detected minimal
enhancement of CD69 expression in the CD69− fraction
(Supplementary Fig. 3b). To further confirm the residency nature
of most of the cervical cells supporting infection, we stimulated 10
day-infected tissue blocks with CCL19, CCL21, and S1P overnight
to attract non-TRM out of the tissue in a transwell migration assay.
CCL19 and CCL21 are chemokine-ligands attracting CCR7
expressing cells, while S1P promote egress of cells expressing
S1PR140. Next day, we determined the level of infection in tissue
blocks, as well as in the supernatant (Supplementary Fig. 3c). This
experiment demonstrated higher frequency of p24+ cells retained
within the tissue compared to the supernatant (Supplementary
Fig. 3c). In addition, CD69 expression in total CD8− T cells was
higher within the tissue (~60–81%) than in the supernatant
(~35–52%). Interestingly, while productive infection was again
strongly associated to the TRM phenotype in the tissue (with >72%
of the p24+ cells expressing CD69), most of these infected cells did
not express the α-chain of the IL-7 receptor, CD127, also associated
to the TRM phenotype in healthy cervical tissue (Supplementary
Fig. 3c).
Lastly, in four of these cervicovaginal explants infected ex vivo,
in which, after tissue processing, a high number of T cells were
obtained, we further purified CD4+/− TRM expressing CD32 to
determine their vDNA content. Although limited by the small
number of experiments, there was a trend towards higher content
of vDNA per cell in CD32+ vs. CD32− CD4+/− TRM (Fig. 3f). In
addition, although most of the p24+ cells were not CD32+, CD32
expression was significantly more frequent in p24+ TRM
compared to p24− TRM (p= 0.008, Fig. 3g). Taken together,
these results indicate that CD4+ TRM preferentially support HIV
infection ex vivo, as demonstrated by higher vDNA content per
cell and by high expression of intracellular p24 viral antigen.
These data concur with recently reported high CD69 expression
on infected tonsillar T cells and predicted precursor cells,
indicating preferential infection of these cells, as opposed to
HIV-induced changes in receptor expression41. It remains to be
elucidated if CD32 expression on CD4+ TRM remains stable in
the HIV-1 infected cells over the virus life cycle or is modulated
by infection, and mostly associated to a fraction of activated cells
as proposed10.
HIV infection impacts on cervical CD4+ TRM in women. Next
we determined if CD4+ TRM remain in tissue from HIV infected
patients, since they may be impaired as a consequence of the
retroviral infection, as suggested42. Thus we compared cervical
CD4+ T cells from two groups of patients: cervicovaginal tissue of
previously analyzed normal healthy donors (ND) and ART-
suppressed HIV+ patients (Table 1). As expected, the frequency
of CD4+ cells out of total CD45+ lymphoid-cells decreased from
a median of 32.2% in ND to about 20.2% in HIV+ patients (p=
0.002, Fig. 4a). Importantly, the frequency of TRM within the
same fraction was also lower in HIV+ patients compared to ND
(p= 0.006, Fig. 4a). Further, the median of CD32+ TRM out of the
CD45+ lymphoid-cells was of 0.52% in HIV+ patients compared
to 1.87% in ND (p= 0.006, Fig. 4a). Additionally, cervical CD4+
HLA-DR+ T cells were proportionally increased in HIV+ women
with a median of 3.15% compared to 1.29% in ND (Fig. 4a),
similar to what has been described20.
When we determined the frequency of HLA-DR in different
fractions, we observed that in virally suppressed HIV+ patients,
HLA-DR expression was significantly enhanced compared to ND
in total CD4+ TRM (p < 0.0001), TRM CD103+ (p= 0.01), and in
non-TRM (p= 0.001), suggesting a higher degree of activation of
all these cells in infected compared to uninfected tissues (Fig. 4b).
In contrast, the frequency of CD32 in the different subsets was
similar between the two groups, except for a trend to lower
frequencies of CD32+ CD103+ TRM cells in virally suppressed
HIV+ patients compared to ND (p= 0.0756; Fig. 4c). However,
as mentioned earlier, it was clear that CD32 was strongly
associated to the CD4+ TRM phenotype, since higher percentages
of CD32 expression were detected in total CD4+ TRM and CD4+
CD103+ TRM of both groups compared to their corresponding
non-TRM fractions (p < 0.05 for all comparisons, Fig. 4c).
Together, these data suggest a direct impact of HIV infection
on the CD4+ TRM fraction of the lower genital tract, as evidenced
by its depletion and activation, which remains after >10 years of
effective ART suppression in HIV+ women.
TRM are the main cellular reservoir in the cervical mucosa.
Tissue body reservoirs of HIV-1 or SIV have mainly focused on
the analyses of virus burden in blood, lymphoid tissues and
gastrointestinal tract3,16, while other mucosal tissues such as the
female genital tract have not been accurately evaluated for HIV-1
persistence. To address if the cervical mucosa is a site of viral
persistence and if mucosal TRM represent a cellular reservoir, we
compared contemporaneous blood and cervical samples from 8
HIV-infected women who had been ART-suppressed for at least a
year, with a median of 4 years of suppression (Table 1). First, we
compared the total amount of vDNA in total CD4+ and CD4−
(CD8−) T cells from tissue and blood, using the same gating
strategy shown for the ex vivo model to include infected CD4+
T cells that down-regulate this receptor (Fig. 3a). Importantly,
cervical tissue contained significantly more HIV-DNA copies per
106 CD4+/− T cell than blood (p= 0.015; Fig. 5a). While CD4+/−
T cells from blood harbored between 28 and 4812 vDNA copies/
106 CD4+/− T cells, cervical cells contained between 1366 and
23,270 copies per million cells, which corresponded to fold
changes of up to >200 times more provirus per cell in cervix than
in blood (Fig. 5a). Of note, the number of sorted cells highly
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varied based on the sample size and the patient, and probably
limited detection of vDNA in tissue from other patients (Sup-
plementary Table 1). In fact, 15 more samples were also pro-
cessed, but the low yield obtained after tissue processing limited
performing any of these analyses. Nonetheless, patients with
detectable vDNA in cervix had undetectable viral load in blood
for at least 1 year and up to >11 years (Table 1). In cervical tissue
of seven of these patients, by sorting CD69+ TRM and CD69−
non-TRM, we demonstrated that the vDNA detected in these
patients was associated to the TRM fraction in all but one patient,
who had detectable vDNA in both TRM (5073 copies/106) and
non-TRM cells (1606 copies/106). Of note, although in most tis-
sues TRM were purified in higher numbers than non-TRM, in
patient #M04 higher numbers of CD4+/− non-TRM were sorted
(Supplementary Table 1), yet only the CD4+/− TRM fraction was
positive. Thus, we observed that the TRM fraction contained
significantly more vDNA than the whole population of CD4+/−
T cells present in cervical tissue (p= 0.015; Fig. 5b and Supple-
mentary Fig. 4a). Next, we calculated the global contribution of
TRM and non-TRM to the total pool of infected CD4+/− T cells in
cervix of HIV-infected women. For the fractions that were
undetectable for vDNA, we used the limit of detection of the assay
based on the individual cellular inputs and the resulting number
was plotted as the maximum possible contribution. We found
that the TRM subpopulation significantly contributed to the pool
of infected cells by representing a median of 95.65% compared to
4.34% of non-TRM (p= 0.015; Fig. 5c), which was partially due to
their different frequencies (a median of 83.20% and 16.79%,
respectively).
In contemporary blood samples from the same patients, we
used the same flow cytometry panel to isolate four different
fractions from total CD4+/− T cells: CD69+ (in blood identifying
recently activated cells), CD103+ (a potential surrogate marker of
tissue-derived T cells43,44), CD32+ (here not CD69 or CD103)
and CD4+/− T cells not expressing any of these three markers
(Fig. 5d). We detected similar median levels of vDNA content in
all subsets and no statistical differences were observed among
them (Fig. 5d), regardless of different sorted cell numbers
(Supplementary Table 1). However, when we analyzed the
contribution of the different subsets to the blood reservoir, most
of the contribution to the total pool of HIV in CD4+/− T cells
was due to CD69−CD103− CD32− CD4+/− T cells, since they
were the most frequent subset, representing >96% of the CD4+/−
T cells (p= 0.0002) (Fig. 5e). It is noteworthy that when we
analyzed the phenotype of these PBMC from HIV+ patients, we
detected that in blood CD32 was also strongly associated to
the CD69 fraction, in which a median of 38.2% of the cells
expressed CD32 (p= 0.004 compared to total CD4+/− T cells,
Supplementary Fig. 4b). On the other hand, HLA-DR protein
expression was enriched in the CD69+ and the CD103+ fractions
(p= 0.008 for CD69+, p= 0.004 for CD103+ compared to total
CD4+/− T cells, Supplementary Fig. 4b). This implies that we
partially decreased the total frequency of CD32+ CD4+/− T cells
by gating on CD69+ CD4+/− T cells (which represented a
median of 8.1% of the total CD32), thus underestimating their
contribution to the total reservoir in blood. Simultaneously, the
contribution of the CD69 fraction to the total pool of cells is
strongly sustained by its high expression of CD32. Further
Table 1 Clinical data of HIV-infected patients included in the study
# Patient ID Analyses Age (yr) Time since HIV
diagnosis (yr)
Viral load
(copies/ml)
CD4 cell count
(cells/µl)
Time on ART-
suppressed (yr)
ART regimen
M00 DNA 55 >12 <50 566 >10 TDF+ FTC+ ETR
M01 Flow 51 3.41 <50 420 3 3TC+ABC+DTG
M02 DNA/Flow 52 27 <50 940 13.58 3TC+ABC+ RAL
M03 DNA/Flow 54 16.58 <50 1260 16 TAF+ FTC+ EVG/c
M04 DNA/Flow 26 4 <50 520 3.67 3TC+ABC+DTG
M05 DNA/Flow 57 27 <50 1400 15.33 TDF+ FTC+ EVF
M11 Flow 44 13.16 <50 440 11.66 3TC+DRV/c
M15 Flow 48 29.50 <50 380 16.50 3TC+ABC+DTG
M16 Flow 49 30.50 <50 490 2.64 DRV/c+DTG
M17 Flow 47 26.58 <50 820 20.67 3TC+ABC+DTG
M18 Flow 63 19.54 <50 160 18.45 3TC+DTG
M19a Flow 51 31.50 <50 200 6.82 DRV/c+DTG
M20a DNA/Flow 53 29 <50 1257 1.46 ATV/r+ 3TC+ ddI
M21 Flow 49 22.79 <50 850 14.66 3TC+ABC+NVP
M22 DNA/Flow 48 26.50 <50 850 2.55 3TC+ABC+DTG
M23a DNA/Flow 46 23.46 <50 2850 2.09 3TC+DTG
M25 DNA/Flow 48 17.62 <50 1040 13.87 EVG/c+ FTC+ TAF
M26 Flow 44 26 <50 511 >15 3TC+ABC+DTG
M27a Flow 54 34.39 <50 1380 0.71 DRV/c+ RPV
M28 DNA 54 20 <50 750 4.5 3TC+ABC+DTG
P1 RNA 34 9.5 5100–10,400 760 − UNTREATED
P2 RNA 30 3.42 <50 380 3.16 3TC+ABC+DRV
+ RTV
P3 RNA 49 4.25 <50 910 4 3TC+ABC+DTG
P4 RNA 49 0.5 <50 280–350 0.25 TAF+ FTC+ EVG/c
P5a RNA 47 24.16 <25 811 4 EFV+ FTC+ TDF
P6 RNA 51 11.25 <25 215 2 EFV+ FTC+ TDF+
EFV
P7 RNA 46 20.16 <25 828 5.5 DRV
aAll infections correspond to diagnosed heterosexual HIV-1 transmission except M19, M20, M23, M27, and P5, which used to be injecting drug-users. TDF tenofovir disoproxil fumarate, FTC emtricitabine,
ETR etravirine, 3TC lamivudine, ABC abacavir, DTG dolutegravir, RAL raltegravir, TAF tenofovir alafenamide fumarate, EVG/c elvitegravir boosted with cobicistat, EVF efavirenz, NVP nevirapine, DRV/c
darunavir boosted with cobicistat, DRV darunavir, RTV ritonavir, RPV rilpivirine, ATV atazanavir, ddI didanosine
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analyses discriminating these two fractions should determine
their separate real contribution to the viral reservoir in blood.
Finally, by including CD4− (CD8−) T cells in these analyses we
enriched the fraction of activated cells, since CD4− T cells from
blood expressed significantly more CD69, HLA-DR, CD103 and
CD32 than CD4+ T cells (p= 0.004 for CD69 and HLA-DR, p=
0.012 for CD103, p= 0.019 for CD32, Supplementary Fig. 4c), while
in cervix only CD32 was associated to the CD4− fraction of T cells,
yet HLA-DR had a strong opposite trend (p= 0.004 for both,
Supplementary Fig. 4d). Of note, in terms of general expression,
both CD32 and HLA-DR frequencies were higher in cervicovaginal
cells than in blood of HIV+ patients, indicating that a fraction of
tissue-resident cells are potentially more activated than circulating
cells. In any case, altogether, these results provide evidence that
CD4+ TRM are infected in vivo and represent an HIV target, at least
in cervical tissue. Importantly, regardless of effective ART-
suppression for more than 10 years, high levels of proviral DNA
are still detected in CD4+ TRM from the cervical mucosa of HIV+
women, consistently suggesting that this cell type could represent an
important cellular reservoir elsewhere.
HIV−RNA+ CD69+ cells are detected in cervical tissue. We
used in situ hybridization (ISH) to determine if cervical tissue
harbors vRNA+ cells, as performed before10,45,46, and if these cells
co-express CD69. We performed this by combining ISH for HIV-
1 viral RNA with immunohistochemistry of CD69, since CD69
mRNA expression was hardly detectable (data now shown).
Cervical preparations from one untreated viremic controller and
six ART-suppressed women were examined (Table 1, #P1-P7). In
the cervical mucosa of the viremic controller patient we detected
vRNA+ cells co-expressing CD69 in both the epithelium and the
lamina propria (Fig. 6a). As shown in the associated pie charts,
from the total of 15 HIV-vRNA+ cells detected in this sample,
close to 73% were located in the submucosa and the rest in the
epithelium (Fig. 6a). Although a lower proportion of CD4+ TRM
are found in the intraepithelial compartment compared to CD8+
TRM, CD4+ TRM are retained in both compartments47. Interest-
ingly, some of the vRNA+ cells in the submucosa were associated
to CD69 enriched zones (45% of them), which could concur with
previously described semi-organized lymphoid structures con-
taining resident memory lymphocyte clusters48,49. Of note, the
strong staining of the HIV-1 RNA probe in some positive cells
precluded distinctive determination of CD69 positivity and thus
we did not count double positive cells in each compartment.
Importantly, when we examined cervical preparations of ART-
suppressed HIV+ women, we also detected vRNA+ cells expres-
sing CD69 in the epithelium and the submucosa (Fig. 6b). In these
patients the overall mean frequency of HIV-vRNA+ cells was of
0.114 cells/mm2, which was similar to what was observed in the
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Fig. 4 Impact of HIV infection on CD4+ TRM cell subsets from cervix. a Frequency of cervical CD4+, TRM, TRM CD103+, TRM CD32+, and HLA-DR+ CD4+
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correction for multiple comparisons for intra-group comparisons. Source data are provided as a Source Data file
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cervical tissue from the viremic controller woman, where we
detected 0.106 cells/mm2. In five ART-suppressed HIV infected
women where the epithelium was preserved, >70% of the vRNA+
cells were found in the submucosa of the cervix, in general less
frequently associated to high density CD69+ staining, as shown in
the pie charts for #P2 (Fig. 6b). Individual quantification and
distribution of vRNA+ cells in different tissue areas is shown in
Fig. 6c, d for all patients. In any case, these analyses demonstrate
substantial residual viral transcription in the cervical mucosa of
ART-suppressed women often associated to CD69+ and thus
to TRM.
Discussion
Here we assert the existence of an overlooked HIV-1 reservoir in
cervical tissue from women, since we detected substantial levels of
HIV-1 DNA and RNA in the mucosa of ART-treated patients
with undetectable plasma viral load for up to 10 years. Moreover,
we identify CD4+ TRM as a critical cellular reservoir that sustains
persistence in peripheral tissues. This subset, recently character-
ized in multiple tissues, includes highly HIV-susceptible pheno-
types in the female genital tract, which are simultaneously shaped
for long-term permanence in tissues. Accordingly, and con-
sidering the proportion of CD4+ T cells estimated to belong to
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Fig. 5 Cellular reservoirs in CD4+/− T cells from cervix and blood of ART-suppressed HIV-1 infected women. a Comparison of HIV-1 DNA molecules per
million CD4+/− T cells in cervix and PBMCs from the same ART-treated women (n= 8). b Comparison of HIV-1 DNA molecules per million CD4+/−
T cells and per million CD4+/− CD69+ (TRM) in cervix from seven ART-suppressed women. c Individual contribution of CD4+/− TRM and non-TRM to the
total HIV reservoir in cervicovaginal tissue (left) and summary data from all patients (right). d HIV-1 DNA molecules per million cells in four different
subsets based on the expression of CD69, CD103 and CD32 in CD4+/− T cells from blood in HIV-infected women (n= 9). Empty circles represent values
under the limit of detection. e Contribution of analyzed subsets to the total HIV reservoir in blood (left) and summary data from all patients (right). Boxes
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the TRM phenotype in tissues all over the human body25,26, the
contribution of this subset to HIV-1 persisting reservoirs may be
of great importance. In fact, among these tissues with large
proportions of TRM we find lymphoid and mucosal sanctuaries
such as the gut, estimated to be the main reservoirs during
treatment3. Thus, dissecting CD4+ TRM heterogeneity in relation
to HIV pathogenesis and determining the relative weight of
specific CD4+ TRM subsets as cellular reservoirs should be a
priority for the HIV field.
TRM longevity in diverse sites may reflect the accumulation of
antigenic experiences over the human lifespan25, which may be
particularly relevant in peripheral tissues that represent a mucosal
barrier against a broad range of microbes, such as the female
genital tract. However, TRM of the cervicovaginal mucosa of
women have not been characterized in depth, regardless of being
a site of exposure to many viral and bacterial infections with very
high global burden. Recent efforts to define transcriptional and
functional signatures of CD69+ TRM have revealed consistent
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patterns across human tissues, but also increased heterogeneity of
the CD4+ TRM fraction compared to CD8+ TRM25,26. Here we
confirm that expression of CD69 in human cervical mucosa
associates to a protein signature identifying bona fide TRM in
>95% of these cells25,26,31,32, which suggests residency associated
to most CD4+ T cells from the human female genital tract, as
recently reported in the mouse model30. Importantly, we report
that cervical CD4+ TRM from both ectocervix and endocervix
frequently express several surface proteins associated to increased
HIV susceptibility28,36,50,51. In fact, CD4+ T cells derived from
the cervix of HIV− women expressing α4β7, α4β1, or the same
CD69, were already shown to represent preferential targets of
HIV entry28. Our study extends these findings, revealing that the
majority of CCR5+ CD4+ T cells indeed belong to the TRM
phenotype, which is highly enriched in the expression of α4β7
and α4β1 integrins, as suggested50, but also in HIV-1 co-receptors
such as CXCR4 or CXCR637. Further, CCR6 expression, which
may indicate a Th17 response, was also more frequent in CD4+
CCR5+ TRM from the endocervix. Importantly, Th17 cells not
only represent preferential targets after SIV vaginal transmis-
sion51, but also are enriched for replication-competent HIV-1
DNA in colon and blood from ART-treated patients52.
Critically, we confirmed that TRM are indeed preferentially
infected in human cervical tissue explants infected with HIVBaL,
where this phenotype harbored more vDNA and was more pro-
ductively infected than their counterparts, CD69− non-TRM. As
mentioned, by using high-dimensional CyTOF analysis, Cavrois
et al. recently demonstrated preferential infection of tonsillar
CD69 positive cells, where predicted precursors of the HIV-
infected cells had similarly high expression levels as the infected
cells41. Although we cannot discard that non-TRM present in the
cervical tissue may upregulate CD69 upon HIV infection, the
preference to support HIV-infection of sorted CD69+ cervical
CD4+ T cells, the lack of CD69 up-regulation after HIV-exposure
in the sorted CD69− fraction, the dynamics of the expression of
CD69 and HLA-DR during infection overtime, the infection level
observed in CD103+ TRM, and the fact that most of the pro-
ductive infection is retained within the tissue even after stimu-
lation with S1P and CCR7-ligands, strongly suggest an important
role for TRM supporting HIV infection, as implicit on the work
from others18,27,28. The down-regulation of CD69 detected in
cervical tissue culture has already been observed in the tonsil
explant model53 as well as in adipose tissue18, and could be
related to disruptions on cell trafficking and retaining stimulus.
However, in the tonsil explant model, there was an increase in
activation measured by HLA-DR and CD25 expression over
time53 that was not observed in our results. Moreover, although
culturing tissue may affect retention signals, CD69 expression
remained higher within the tissue blocks compared to the cells
that emigrated in the supernatant, confirming its association with
mucosal retention. Importantly, after 10 days of infection, most of
the productively infected cells remained associated to the TRM
phenotype within the tissue. Thus, in principle, CD4+ CCR5+
TRM from a wide range of peripheral mucosal and lymphoid
tissues may represent preferential targets of HIV infection.
Interestingly, we detected a small subset of cervical CD4+
CCR5+ TRM that readily expressed CD32, a marker originally
associated to HIV-latently infected cells9, which was later linked
to transcriptionally active infected cells10–13. We observed that
the fraction of TRM expressing CD32 was enriched for most of the
molecules investigated, many of them associated to HIV sus-
ceptibility. The fact that CD32 expression was strongly associated
to cells expressing the highest levels of CD69 may explain why
these cells are enriched for most of these molecules, since many
are connected to the TRM phenotype definition per se25. We also
observed an association between CD32 and CD69 expression in
peripheral blood of these ART-suppressed patients, and CD32+
CD69+ CD4+ T cells have already been shown to correlate with
proviral DNA in blood10. Supporting their higher susceptibility to
HIV infection in cervix, we detected remarkably high copies of
HIV-1 DNA per cell associated to this fraction. Moreover, the
overall level of tissue infection appeared to determine the level of
infection of the CD32− TRM fraction, where less infection mag-
nified the preference towards CD32 expressing TRM. Further,
productively infected cells expressed more CD32 than uninfected
TRM and these cells were associated to higher expression of HLA-
DR, as recently reported10. Therefore, CD32 expression in CD4+
TRM could identify a subset remarkably susceptible to HIV-1
infection, potentially highly activated within an overall more
quiescent TRM compartment, which may or may not continue to
express this marker throughout the different stages of the retro-
viral infection. Future studies will confirm if CD32 is indeed
predicted in the precursors of HIV-1 infected cells and if no
down-regulation occurs in between HIV-1 infection stages. Our
results, including the increased coexpression of IL-receptors in
this subset, together with the fact that a recent paper demon-
strates higher proportion of HIV-RNA+ cells co-expressing
CD32-RNA in ART-suppressed than in viremic individuals13,
highlight the need to better understand the dynamics of CD32 in
the context of tissue reservoir establishment and persistence.
We found that HIV infection has long-term consequences for
the CD4+ TRM population of the cervical mucosa. In cervix from
ART-suppressed women, the frequencies of CD4+ and CD4+
TRM cells out of the total CD45+ lymphocytes decreased com-
pared to tissues from uninfected women, and these cells expressed
higher percentages of HLA-DR. Concomitant cervical viral
infections such as herpes simplex virus type 2 (HSV-2) or human
papilloma virus (HPV) have been associated with systemic T cell
Fig. 6 Detection of HIV-RNA+ CD69+ cells in the cervical mucosa of virologically suppressed women. Paraffin-embedded cervical tissue from one viremic
and six ART-suppressed HIV-infected women were stained for HIV-1 RNA (rose) using the RNAscope 2.5 HD Duplex Reagent Kit in combination with
immunohistochemistry of CD69 protein (brown). a Two representative images of a viremic HIV-infected patient (#P1) with a cell co-expressing HIV-1 RNA
and CD69 in the epithelium (left) and in the submucosa (right) are shown inside a white square. Lower panels show high magnification of each of these
squares. Scale bar is 100 µm and 20 µm in top and bottom panels, respectively. Left pie chart shows the proportion of HIV-RNA+ cells detected in the
epithelium (light blue) or in the submucosa (dark blue) from the total of 15 HIV-RNA+ cells detected in the cervix of #P1. Right pie chart shows the
proportion of HIV-RNA+ cells detected in the submucosa associated to CD69 enriched clusters (dark brown) or independent from CD69 clusters (light
brown). b Two representative images of an ART-suppressed HIV-infected patient (#P2) with a cell co-expressing HIV-1 RNA and CD69 in the epithelium
(left) and in the submucosa (right) are shown inside a white square. Lower panels show high magnification of each of these squares. Scale bar is 100 µm
and 20 µm in top and bottom panels, respectively. Pie charts represent the same proportions as in a for a total of 11 HIV-RNA+ cells detected in the cervix
(left) or of 8 HIV-RNA+ cells in the submucosa (right) of #P2 patient. c Comparison of positive cells harboring vRNA per square millimeter in the
epithelium and the submucosa of n= 7 HIV-infected patients. Triangle symbols correspond to a viremic patient and circle symbols correspond to data from
ART-suppressed patients. Statistical comparisons were performed using Wilcoxon matched-pairs signed rank test. d Distribution of HIV-RNA+ cells in
different localizations of the cervical tissue in n= 7 HIV-infected patients. Source data are provided as a Source Data file
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activation54,55, which could be conditioning our results. While
Spain has low prevalence of HSV-2 infection compared to other
countries and regions56,57, six out of the 19 patients included in
these analyses tested positive for HPV and presented cervical
intraepithelial neoplasia grade II (CIN II). However, HPV and
high-grade CIN on HIV+ women are associated with high cer-
vical CD4+ cell density in both stroma and epithelium54, and we
did not detect any correlation between the studied frequencies
and these conditions. On the other hand, it has been observed
that menstrual blood of HIV-infected patients has lower expres-
sion of the integrin CD103 compared to uninfected women42;
however, we did not detect a significant impact of HIV infection
on the cervical CD4+ CD103+ TRM fraction in our patients.
Although CD103 has been established as one of the core surface
markers for the TRM lineage, CD4+ TRM express lower levels of
this integrin compared to the CD8+ fraction25, which may be
related to higher intraepithelial retention of CD8+ vs. CD4+
T cells47. Still, detection of HIV-1 RNA in cervical tissue from
women demonstrated intraepithelial and submucosal positive
cells, highlighting the presence of these cells in close proximity to
the mucosal surface, which has obvious implications for HIV
acquisition. In this sense, Hladik et al. demonstrated that
intraepithelial vaginal CD4+ T cells, which highly expressed the
major HIV-1 coreceptors (CD4 and CCR5), were remarkably
permissive to HIV-1 infection58. It remains to be elucidated how
long these cells remain within these mucosal tissues and if it they
can establish a latent cellular reservoir.
Generation of CD4+ TRM has been associated to protection
against herpesvirus in the female genital tract of mice48, and it is
also believed to limit recurrence in humans47. In mice, protective
CD4+ TRM were found in macrophage-organized memory lym-
phocyte clusters that developed after vaginal but not systemic
attenuated infection48. Protection against other sexually trans-
mitted infections such as Chlamydia is also associated to presence
of effective CD4+ TRM in the genital mucosa47,49. Female
reproductive tract conditions, such as bacterial vaginosis, induce
an increase in the expression of α4β1 and CCR5 of circulating
effector CD4+ lymphocytes59, which may correspond to recruited
cells that contribute to the establishment of a memory pool.
Remarkably, it is now clear that pre-existing TRM populations are
not displaced after subsequent infections, which enables multiple
TRM specificities to be stably maintained within the tissue, as
recently shown in the skin29. Thus, in principle, infections over
the lifetime of an individual will contribute to increase the TRM
pool. Further, novel vaccine designs combining a general prime
strategy with recruitment of activated T cells to the genital tract
(by means of topical chemokine application) have been proposed
to establish local memory and prevent reinfection48. However, in
the context of HIV infection, establishment of these clusters of
CD4+ TRM may also provide increased number of HIV-1 targets
for the nascent infection, which can ultimately contribute to a
larger reservoir after treatment. In this sense, we detected CD69+
enriched areas compatible with TRM clusters in the cervical
submucosa of ART-suppressed patients that contained tran-
scriptionally active HIV cells. Therefore, past and concomitant
infections of the genital tract may contribute to lowering the
threshold for HIV acquisition60 by increasing preferential TRM
targets and, in addition, augment long-lived cellular reservoirs.
The effect of cytokines on the maintenance and homeostatic
proliferation of certain populations of memory lymphocytes may
be determinant in the establishment and durability of reservoirs,
as occurs for IL-7 driven homeostatic proliferation of latently
infected cells5 or for IL-15 with the TSCM subset61. It seems that
the maintenance of effector memory cells after the contraction
phase of the immune response corresponds to 5–10% of the
effectors that express high levels of CD12762. Thus, it is possible
that the virus takes advantage of this population at the moment of
contraction of the immune response and the transition to a
resting state in order to establish latency in these cells. Further,
while both CD127 and CD57-expressing cells in tonsils are per-
missive to HIV infection, only CD57+ cells lead to productive
infection41. According to detailed phenotyping of TRM in differ-
ent tissues across the human body, maintenance of CD127 and
low expression of CD57 (the latter at least in CD8+ TRM) are
features of TRM25. Additional lack of recent activation markers
and reduced proliferative turnover shape TRM as quiescent long-
lived cells designed for local immunity25. Here we have confirmed
high expression of CD127 in CD4+ TRM from the cervical
mucosa, as well as increased expression of CD122 and CD132,
with low expression of HLA-DR, suggesting that they indeed
could constitute a long-term stable reservoir. Further, we also
concur the lack of expression of CD127 among productively
infected cells, thus it remains to be determined if this receptor can
identify latently infected subpopulations of TRM in HIV patients.
Consistent with this idea, it has been shown that stimulation with
IL-7 induces reverse transcription and virus integration63, while
addition of this cytokine to the cervical explant model enhances
HIV replication by promoting not only proliferation but also
survival of infected cells64. The fact that cervical TRM express high
levels of these receptors reinforces their potential contribution to
HIV persistence in these tissues.
Importantly, regardless of long ART-mediated viral suppres-
sion, we detected very high levels of proviral DNA in the TRM
fraction of cervical tissue from HIV+ treated patients. The values
of HIV-1 DNA copies detected here concur with recent data
reporting higher provirus copy numbers found in the lamina
propria of vaginal tissue of a single ART-treated woman com-
pared to PBMC21. In addition, our results on proviral DNA are
remarkably similar to the ones determined in ileum biopsies16
and in bronchoalveolar lavage17 from ART-suppressed patients,
in which effector memory phenotypes were reported to sustain
these reservoirs. Since most tissue TRM express phenotypic mar-
kers that would classify them as circulating memory effector cells,
based on the expression of CD45RA and CCR726, it seems
plausible that the aforementioned reservoirs are largely composed
of TRM phenotypes. Still, in blood samples from ART-treated
patients, most of the HIV-1 DNA detected contains fatal muta-
tions and only 2–10% of proviruses are estimated to be intact,
indicating that only a minor fraction is more likely to produce
replication competent virus,65. Moreover, we showed that after
long-term ART, TRM contained transcriptionally active HIV.
Although we performed a quantitative viral growth assay in
sorted TRM obtained from cervix of one hysterectomy, the small
number of cells recovered limited this assay. Future studies
involving techniques with lower cell number requirement may
better clarify the portion of intact virus within TRM from the
cervix of ART-treated women66. However, the fact that a recent
study reports that proviral copy numbers correlate with levels of
cell-associated HIV RNA and predict control after treatment
interruption55 denotes the importance of the remaining levels of
vDNA and vRNA encountered in this study. These findings
recognize this subpopulation of cells, not only as a long-term
cellular reservoir for HIV, but also as the possible source of
residual viremia observed in HIV+ patients despite ART. In this
sense, a high degree of variability in penetration of the different
antiretroviral drugs, both between and within drug classes, has
been reported in the female genital tract67, potentially con-
tributing to this phenomenon, as observed in other tissues3,4.
In summary, in this study we have identified, CD4+ TRM as a
critical cellular reservoir of the cervical tissue, and most likely of
other tissues not yet identified. These cells are preferentially
infected during ex vivo HIV infection and, after years of
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suppressive treatment, still harbor HIV-1 nucleic acids in the
cervical mucosa of infected women. With current clinical guide-
lines recommending early ART initiation, the relevance of
mucosal tissues where the virus first replicates as sources of viral
persistence may increase in years to come. Overall, the con-
tribution of CD4+ TRM to viral persistence in lymphoid and
mucosal tissues as well as their capacity to establish latent or
active viral reservoir in these tissues requires major attention in
order to reach a functional cure in HIV infected patients.
Methods
Study subjects and patient samples. Cervical tissue was obtained from non-
neoplastic hysterectomies ranging 26–74 years performed in participating hospi-
tals. Additionally, blood and cervical tissue from ART-treated HIV+ women were
obtained from women undergoing a hysterectomy or a cone biopsy in the same
hospitals. Study protocols were approved by the corresponding Ethical Committees
(Institutional Review Board numbers PR (IR)294/2017 for the HUVH, PI-17–159
for the HUGTP and 2018/8017/I for the Parc de Salut Mar), and written informed
consent was provided by all patients recruited to this study. Patient information on
plasma viral loads, CD4+ T cell counts, time of ART-suppression and treatment is
summarized in Table 1.
Cervical tissue digestion and flow cytometry phenotyping. A piece of ectocervix
and endocervix from healthy donors was delivered to the laboratory once healthy
tissue status was confirmed by the Pathology Service. Tissue was delivered in
antibiotics-containing RPMI 1640 medium and processed within the 24 h following
surgery68. The mucosal epithelium and the underlying stroma were separated from
the muscular tissue and dissected into ~8-mm3 blocks. Tissue blocks were then
enzymatically digested by incubating them with 5 mg/ml collagenase IV in RPMI
1640 5% FBS for 30 min at 37 °C and 400 rpm, followed by a mechanical dis-
sociation of the tissue with a disposable pellet pestle68. Once digested, the cellular
suspension was washed twice with PBS and stained with Live/Dead Aqua (Invi-
trogen) to identify dead cells. After washing, cells were equally divided into 5
different tubes and stained with the following antibodies: HLA-DR-PerCP-Cy5.5
(G46-6 dilution 1/100, cat. no. 560652), CD14-V450 (MØP9, dilution 1/40, cat. no.
560349), CD69−Horizon-PE-CF594 (FN50, dilution 1/20, cat. no. 562645), CCR5-
APC-Cy7 (2D7, dilution 1/50, cat. no. 557755), CD163-BV786 (GHI/61, dilution 1/
20, cat. no. 741003), CD4-BV605 (RPA-T4, dilution 1/12.5, cat. no. 562658),
CD19-V500 (HIB19, dilution 1/50, cat. no. 561121), CCR7-PE (3D12, dilution 1/
10, cat. no. 552176), CD49d-FiTC (9F10, dilution 1/25, cat. no. 560840), β7-APC
(FIB504, dilution 1/50, cat. no. 551082), CD184-APC (12G5, dilution 1/40, cat. no.
555976) (all from BD Biosciences), CD3-SuperBright 645 (OKT3, dilution 1/20,
cat. no. 64-0037-42), S1PR1 (CD363)-eFluor660 (SW4GYPP, dilution 1/72, cat.
no. 50-3639-42) (eBiosciences), CD45-Alexa Fluor 700 (Hl30, dilution 1/100, cat.
no. 304024), CD32-PE-Cy7 (FUN-2, dilution 1/50, cat. no. 303214), CD103-FiTC
(BER-ACT8, dilution 1/50, cat. no. 350203), CD49a-PE (TS2/7, dilution 1/200, cat.
no. 328303), CXCR3-FiTC (G025H7, dilution 1/33.3, cat. no. 353703), CD127-
FiTC (A019D5, dilution 1/100, cat. no. 351312), CD132-PE (VI C-89, dilution 1/
100, cat. no. 338606), CD122-APC (TU27, dilution 1/100, cat. no. 339008), CCR6-
APC (G034E3, dilution 1/100, cat. no. 353416) (all from BioLegend), CXCR6-APC
(56811, dilution 1/25, cat. no. FAB699A), CCR2-PE (48607, dilution 1/33.3, cat. no.
FAB151P) (R&D Systems), TCR-γδ-FiTC (11F2, dilution 1/40, cat. no. 130-096-
884) and CD161-PE (191B8, dilution 1/50, cat. no. 130-092-677) (Miltenyi Biotec).
Staining of T-bet (T-bet-BV421, 4B10, dilution 1/40, cat. no. 644815, Biolegend),
Eomes (Eomes-PE-Cy7, WD1928, dilution 1/33.3, cat. no. 25-4877-42, eBioscience)
and Hobit (Hobit-AF647, Sanquin-Hobit/1, dilution 1/20, cat. no. 566250, BD
Biosciences) was performed using FoxP3 transcription factor staining buffer set
(eBioscience), according to manufacturer’s protocols. Preliminary controls on the
effect of collagenase IV treatment on the stability of the cell surface markers
analyzed were performed in PBMC68. Fluorescence Minus One (FMO) controls
were performed to delineate gates of continuous markers in at least one tissue
sample. Samples were acquired in a BD LSRFortessa flow cytometer and analyzed
with FlowJo vX.0.7 software (TreeStar).
Flow cytometry imaging of CD32 expressing cervical TRM. Specific analysis of
CD32 expression on cervical CD4+ cells was performed by using Amnis® tech-
nology. To do so, digested tissue cells were stained with CD32-PE (FUN-2 dilution
1/20, cat. no. 303205), CD45-Alexa Fluor 700 (Hl30, dilution 1/100, cat. no.
304024, both from BioLegend), CD69-FITC (FN50, dilution 1/20, cat. no. 557049),
CD4-BV605 (RPA-T4, dilution 1/12.5, cat. no. 562658 both from BD Biosciences)
and a viability dye (LIVE/DEAD Fixable Violet Dead Cell Stain Kit, dilution 1/250,
cat. no. L34966, Invitrogen), and then acquired with an AMNIS ImageStremX
imaging flow cytometer (Merck). Data were analyzed using IDEAS v6.1 software.
Gradient RMS value > 40 was established as a threshold for best focus, and only
focused cells were considered for analysis. A CD32-FMO control was performed to
delineate this gate in CD69+ and CD69− cervical CD4+ cells.
Explant infection and subset purification. Eight to twelve blocks of tissue per
condition were placed in RPMI1640 media supplemented with 20% FBS (R20) in a
24-well plate and infected with 7200 TCID50 of the viral stock HIV-1BaL or medium in
control wells. For each experimental condition at least duplicates were performed.
After 2 h of incubation at 37 °C, tissue blocks were washed three times with 3mL of
PBS in 6-well plates and placed back into a 12-well plate at 8 blocks/well in 1mL of
R20. Infected cervical tissue blocks and controls were cultured for additional
10–12 days, with a change of medium every 3 days. Tissue digestion with collagenase
IV (Invitrogen) and manual dissociation were immediately executed, as described
above68. Supernatants and cell suspensions were incubated with Aqua vital dye and
stained with CD69-Horizon-PE-CF594 (FN50, dilution 1/20, cat. no. 562645), CD4 or
CD127-BV605 (RPA-T4, dilution 1/12.5, cat. no. 562658 and A019D5, dilution 1/100,
cat. no. 351333 respectively), CD19-V500 (HIB19, dilution 1/50, cat. no. 561121),
CD3-PerCP (SK7, dilution 1/10, cat. no. 345766), CD14-APC-H7 (MφP9, dilution 1/
66.7, cat. no. 560180), CD8-APC (RPA-T8, dilution 1/40, cat. no. 555369), HLA-DR-
BV421 (G46-6, dilution 1/200, cat. no. 562804) (all from BD Biosciences), CD49a-
APC-Vio770 (REA1106, dilution 1/50, cat. no. 130-119-410, Miltenyi Biotec), CD45-
Alexa Fluor 700 (Hl30, dilution 1/100, cat. no. 304024), CD32-PE-Cy7 (FUN-2,
dilution 1/50, cat. no. 303214) and CD103-FiTC (BER-ACT8, dilution 1/50, cat. no.
350203) (BioLegend). After surface staining cells were intracellularly stained with
KC57-PE antibody (FH190-1-1, dilution 1/40, cat. no. 6604667, Beckman Coulter,
Brea, CA) using Fixation & Cell Permeabilization Kit (Invitrogen) according to
manufacturer’s instructions to determine p24 expression10. 1% PFA fixed samples
were acquired in a BD FACSAriaTM II Cell Sorter for purification of Aqua−CD19−
CD45+ CD3+ CD8−CD4± T cells: 1) TRM as CD69+; 2) non-TRM as CD69− and 3)
CD32+ TRM as CD69+CD32+. These samples were immediately lysed and stored for
posterior vDNA analyses by qPCR as follows. Further, samples were acquired for
phenotype analysis using FlowJo vX.0.7 software.
Cervical TRM purification and infection. Cervical tissue from healthy donors was
obtained and digested, and the resulting cell suspension was stained for viability with
Aqua vital dye (Invitrogen) and the following antibodies: CD69-FiTC (FN50 dilution
1/20, cat. no. 557049), CD45-PE (HI30, dilution 1/100, cat. no. 560975), CD3-PerCP
(SK7, dilution 1/10, cat. no. 345766), CD19-V500 (HIB19, dilution 1/50, cat. no.
561121), PD1-BV421 (EH12.1, dilution 1/20, cat. no. 562516) (all from BD Bios-
ciences), CD4-APC (OKT4 BioLegend, dilution 1/80, cat. no. 300514). Aqua−
CD19−CD45+ CD3+ CD4+ T cells were acquired in a BD FACSAriaTM II Cell Sorter
and separated according to their CD69 expression into CD69+ (TRM) and CD69−
(non-TRM). Sorted cells were then infected with 3655 TCID50 of the viral stock HIV-
1BaL for 4 h at 37 °C or with medium in control conditions, washed with PBS and
cultured in a 96-wells plate. After three days, cells were stained for viability with Live/
Dead Fixable Far Red (Invitrogen), CD69-FiTC (FN50 dilution 1/20, cat. no. 557049)
and HLA-DR-PerCP-Cy5.5 (G46-6, dilution 1/100, cat. no. 560652), before staining
for p24 as described above. Fixed cells were finally acquired in a BD FACS Calibur
flow cytometer and analyzed with FlowJo vX.0.7 software (TreeStar).
Cervical TRM migration assay. Nine blocks of tissue per experimental condition
were infected and cultured for 10 days as described above. On day 10, tissue was
transferred to a transwell insert containing CCL19 (100 ng/ml, Biolegend), CCL21
(100 ng/ml, R&D) and sphingosine-1-phosphate (S1P, 10 µM, Sigma) in the lower
chamber medium (R20). Triplicates were established for each experimental condition,
as well as the corresponding controls. Tissue was left overnight at 37 °C and then
digested as described above. Migrating and tissue resident cells were stained separately
for viability, surface markers listed above and p24, fixed, acquired in a BD FAC-
SAriaTM II Cell Sorter and analyzed with FlowJo vX.0.7 software (TreeStar).
Sample subset purification from ART-treated HIV+ patients. Samples from
blood and cervical tissue from HIV-infected women under suppressive ART were
processed to obtain PBMC by Ficoll–Paque density gradient centrifugation or a cell
suspension from digested tissue, as described above. Cells were surface stained with
the same panel described for the ex vivo infection, without p24 intracellular staining.
Fixed cells were isolated by cell sorting using a BD FACSAriaTM II Cell Sorter. In both
tissues sorted cells were Aqua−CD19−CD45+ CD3+ CD4±CD8−T cells and,
depending on the tissue, different subsets were purified: for cervix (1) TRM were
CD69+ and non-TRM were CD69−; for blood (1) CD69+ (CD103− CD32+/−), (2)
CD103+ (CD69− CD32+/−), (3) CD32+(CD69− CD103−) and (4) CD4+/− T cells
did not express any of these three markers (CD69− CD103− CD32−). These samples
were immediately lysed and stored for posterior vDNA analyses by qPCR as follows.
Further, samples were acquired for phenotype analysis using FlowJo vX.0.7 software.
Quantification of cell-associated HIV-1 DNA by qPCR. All sorted subsets
obtained from the ex vivo cervical model or from blood and cervix of HIV+
patients were immediately lysed with a proteinase K-containing lysis buffer (55 °C
over-night and afterwards 5 min at 95 °C) and cell lysates were subjected to total
HIV-1 DNA quantification by qPCR with primers against HIV long terminal
repeat (LTR forward 5′-TTAAGCCTCAATAAAGCTTGCC-3′ and LTR reverse
5′-GTTCGGGCGCCACTGCTAG-3′; LTR probe 5′-CCAGAGTCACACACCA
GACGGGCA-3′). For quantification of total HIV-1 DNA, a standard curve was
prepared and CCR5 gene was used for cell input normalization (CCR5 forward 5′-
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GCTGTGTTTGCGTCTCTCCCAGGA-3′ and CCR5 reverse 5′-CTCACAGCCC
TGTGCCTCTTCTTC-3′; CCR5 probe 5′-AGCAGCGGCAGGACCAGCCCCA
AG-3′). The cycling parameters were 50 °C for 2 min, 95 °C for 10 min and then
95 °C for 15 s and 60 °C for 1 min for 55 cycles of amplification. Contribution of
each subset to the HIV reservoir was calculated by considering the frequency of
each subset (analyzed by flow cytometry) within the total CD4 compartment and
their relative infection frequency.
RNA in situ hybridization and immunohistochemistry. Paraffin-embedded cer-
vical tissue samples from one viremic and six aviremic ART-treated HIV-infected
patients were obtained from the Pathology Department of the HUVH. For detection
of RNA, we used ultrasensitive RNA detection assay RNAscope 2.5 HD Duplex
Reagent Kit (Anacrome). A high sensitivity target-specific probes to GagPol HIV
mRNA sequence were used (bases 507–4601; reference #31769146). Cervical tissue
sections of 5 µm were mounted on Superfrost Plus microscope slides (Fisher Scien-
tific). The assay was performed according to manufacture’s instructions. Briefly,
samples were deparaffinized with xylene and dehydrated in 100% ethanol. Heat-
induced epitope retrieval and protease digestion were used as sample pre-treatment.
Next, probes were incubated for 2 h at 40 °C and samples were stored overnight in 5×
saline sodium citrate buffer. Next day, amplification and signal development of RNA
probes were performed by sequential incubation of indicated reagents. Afterwards, an
immunohistochemisty protocol was carried out. Samples were first blocked by
incubation with 1× Tris-buffered saline buffer containing 1% bovine serum albumin
and 10% normal donkey serum for 30min. Then, anti-CD69 antibody (1/100,
Abcam) was incubated overnight at 4 °C. Antibody detection was performed with
DAB detection kit (Abcam), according to manufacture’s instructions. Images were
captured using a DP71 digital camera (Olympus, Center Valley, PA, USA) attached to
a BX41 microscope (Olympus). Specificity of HIV-RNA positive cells was determined
by quantifying the relative false detection rate in cervical tissues from two HIV
negative patients, which corresponded to 0.03 positive cells/mm2, with no positive cell
detected in their epitheliums or in CD69 enriched areas (Supplementary Fig. 5).
Additional negative controls consisted of a matched sample without target-specific
probes and a control without primary antibody (CD69) for immunohistochemistry
(Supplementary Fig. 5). A cell was considered HIV RNA positive based on the
diameter of the staining, while small punctate signals were not considered in the
quantification46. Positive cells within the whole tissue section were counted by visual
inspection and the total tissue area was measured by ImageJ software.
Statistical analyses. All the data were analyzed using the software GraphPad
Prism 7.0 (GraphPad Software, La Jolla, CA, USA). All values in the graphs are
expressed as the median and the range or the interquartile range. Non-parametric
two-tailed Mann–Whitney rank tests, Wilcoxon matched-pairs signed rank test
and Friedman test with Dunn’s correction for multiple comparisons were used. A
P value < 0.05 was considered significant.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The source data underlying both the Main and Supplementary Figures are provided as a
Source Data file. All other data are available from the corresponding authors upon
reasonable requests.
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